This section includes information and resources about Stroke Prevention in Atrial Fibrillation (AF) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Pradaxa® (dabigatran etexilate) 150mg bid continues to be the only oral anticoagulant which showed superior ischaemic stroke reduction vs. warfarin in its pivotal study RE-LY® – Results of the ENGAGE AF-TIMI 48 trial published for edoxaban vs. warfarin do not change the position of Pradaxa®
New long-term treatment data confirms consistent benefit and safety profile of Pradaxa® beyond 6 years
Boehringer Ingelheim planning two new Global Clinical Trials for Pradaxa® (dabigatran etexilate) in expanded patient populations- For media outside of the US, the UK & Canada only
First human data show promise of Boehringer Ingelheim's specific antidote for immediate, complete and sustained reversal of Pradaxa®-induced anticoagulation
New efficacy and safety data for Pradaxa® (dabigatran etexilate) to be announced at American Heart Association's Scientific Sessions 2013- For media outside of the US, the UK & Canada only
Preventing AF related strokes is vital. Protecting your brain protects your world.